Pages that link to "Q28303689"
Jump to navigation
Jump to search
The following pages link to Molecular mechanisms of patupilone resistance (Q28303689):
Displaying 29 items.
- MiR-200c and HuR in ovarian cancer (Q21261258) (← links)
- Microtubule-binding agents: a dynamic field of cancer therapeutics (Q27690249) (← links)
- Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer (Q28236320) (← links)
- βIII-Tubulin: biomarker of taxane resistance or drug target? (Q28284878) (← links)
- Molecular Mode of Action and Role of TP53 in the Sensitivity to the Novel Epothilone Sagopilone (ZK-EPO) in A549 Non-Small Cell Lung Cancer Cells (Q28477992) (← links)
- Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells (Q28478885) (← links)
- Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations (Q28482107) (← links)
- Microtubules and their role in cellular stress in cancer (Q33770927) (← links)
- Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel (Q33903541) (← links)
- HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer (Q34104074) (← links)
- Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. (Q34126568) (← links)
- Herpes virus microRNA expression and significance in serous ovarian cancer (Q34654294) (← links)
- Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents (Q35583750) (← links)
- Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression (Q35830854) (← links)
- Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer. (Q35929796) (← links)
- Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer (Q36369565) (← links)
- Altered TUBB3 expression contributes to the epothilone response of mitotic cells. (Q36557893) (← links)
- Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. (Q36980135) (← links)
- Improved i.p. drug delivery with bioadhesive nanoparticles (Q37346875) (← links)
- Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin (Q37570220) (← links)
- Proteomics of cancer cell lines resistant to microtubule-stabilizing agents. (Q37625745) (← links)
- Microtubules and resistance to tubulin-binding agents (Q37690565) (← links)
- Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC (Q37800603) (← links)
- Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? (Q38069185) (← links)
- Class III β-tubulin in normal and cancer tissues (Q38404084) (← links)
- High-level βIII-tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome (Q38667965) (← links)
- Random mutagenesis of β-tubulin defines a set of dispersed mutations that confer paclitaxel resistance (Q39336478) (← links)
- An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance (Q39414846) (← links)
- Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. (Q39617351) (← links)